Tarsus Pharmaceuticals, Inc. [TARS] - equity issuance
Tarsus Pharmaceuticals is conducting a private placement of equity expected to close on August 7, 2026, with gross proceeds of approximately $125 million from the sale of shares at $56.00 each and pre-funded warrants at $55.9999 each.
Why this matters
Tarsus Pharmaceuticals, Inc., a Delaware-based company in the biological products industry, is engaged in the development of innovative treatments for various diseases. The company is conducting a private placement of equity, which is expected to close on August 7, 2026, to raise approximately $125 million. This capital is being raised through the sale of shares at $56.00 each and pre-funded warrants at $55.9999 each. In connection with this private placement, Tarsus has entered into a Registration Rights Agreement with investors, requiring the company to file a registration statement with the SEC to cover the resale of the securities. Barclays Capital Inc. acted as the lead placement agent for this transaction.